Table 3

Metabolic profile of HIV-infected patients segregated according to HCV co-infection and antiretroviral therapy

Non-HCV co-infected group

HCV co-infected group



Untreated

NNRTI

PI

Untreated

NNRTI

PI

(n = 19)

(n = 32)

(n = 25)

(n = 32)

(n = 44)

(n = 39)


FASN, μg/L

5.14 (2.10)

7.40 (1.81)

4.15 (1.00)

20.01 (4.0)

8.64 (1.51) b

11.75 (2.41) a

NEFA, mmol/L

0.53 (0.07)

0.63 (0.07)

0.77 (0.1)

0.65 (0.06)

0.67 (0.05) *

0.52 (0.04)

Glucose, mmol/L

5.21 (0.20)

5.77 (0.29) *

5.09 (0.09)

5.13 (0.13)

5.62 (0.19) a

5.21 (011)

Insulin, pmol/L

41.91 (7.1)

70.74 (13.4) a

62.23 (8.6) a

71.35 (11.2)

103.2 (19.8)

72.24 (10.7)

HOMA-IR

0.80 (0.16)

1.38 (0.27) a

1.14 (0.16)

1.41 (0.25)

2.06 (0.42)

1.36 (0.21)

Cholesterol, mmol/L

4.59 (0.24)

5.34 (0.23) a,*

6.10 (0.28) c

4.41 (0.19)

4.67 (0.23)

4.7 (0.16)

HDL-cholesterol, mmol/L

1.18 (0.09)

1.30 (0.12)

1.18 (0.10)

1.17 (0.07)

1.20 (0.05) *

1.09 (0.6)

LDL-cholesterol, mmol/L

2.69 (0.22)

3.10 (0.20) *

3.59 (0.23) a

2.57 (0.15)

2.54 (0.18)

2.70 (1.15)

Triglyceride, mmol/L

1.57 (0.29)

2.60 (0.44) a

4.87 (1.50) b

2.99 (1.71)

2.35 (0.36) a

2.17 (0.22) b

Apolipoprotein AI, g/L

1.39 (0.06)

1.43 (0.07)

1.34 (0.06)

1.33 (0.06)

1.45 (0.04) *

1.32 (0.04)

Alanine aminotransferase, μKat/L

0.52 (0.10)

0.57 (0.11)

0.45 (0.06)

1.16 (0.16)

0.91 (0.11)

0.69 (0.07) a

Aspartate aminotransferase, μKat/L

0.45 (0.07)

0.45 (0.04)

0.41 (0.08)

1.02 (0.13)

0.94 (0.14)

0.69 (0.07) a


Values are the mean and the standard error of the mean (S.E.M.).

HOMA-IR is homeostasis model assessment-estimated insulin resistance; NEFA indicates non-esterificated fatty acids; NNRTI: non-nucleoside analogues reverse transcriptase inhibitors; PI: protease inhibitors;

a P < 0.05, b P < 0.01 and c P < 0.001 vs untreated patients of the corresponding group; * P < 0.05 with respect to PI-treated patients in the corresponding group

Aragonès et al. BMC Gastroenterology 2010 10:92   doi:10.1186/1471-230X-10-92

Open Data